LEPR and Bardet-Biedl syndrome: The drug is specifically indicated for patients with decreased POMC, PCSK1, or leptin receptor (LEPR) or patients diagnosed with a rare genetic syndrome called Bardet-Biedl syndrome that presents with cognitive delays, short stature, and obesity in the pediatric population [76,77].